Published “Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial” in The Lancet — cited 1,092 times.
- #crossref
- #research
- #work